Table 1. Patient characteristics.

Specimen ID	Colon or Rectal	Age at Consent	Primary or Metastatic	Previous Treatment	Stage	KRAS	PIK3CA	BRAF	TP53
CRC-001	Colon	69	Primary	FOLFOX plus bevacizumab	IV	Mut	WT	WT	WT
CRC-006	Colon	42	Primary	Capecitabine plus radiation, FOLFOX plus bevacizumab, Irinotecan plus cetuximab	IV	Mut	WT	WT
CRC-007	Colon	47	Primary	None	II	Mut	WT	WT	Mut
CRC-021	Rectal	71	Primary	None	II	Mut	WT	WT	Mut
CRC-026	Colon	48	Metastatic	FOLFOX plus bevacizumab	IV	WT	WT	WT	WT
CRC-027	Colon	56	Metastatic	None	IV	Mut	WT	Wt	Mut
CRC-036	Rectal	42	Metastatic	Capecitabine plus radiation, FOLFOX plus bevacizumab, Irinotecan plus cetuximab	IV	Mut	WT	WT	WT
CRC-042	Rectal	73	Primary	FOLFIRI plus bevacizumab	II	Mut	WT	WT	Mut
CRC-047	Rectal	58	Primary	None	II	WT	WT	WT
CRC-098	Colonc	50	Metastatic	None	IV	Mut	Mut	WT	Mut
CRC-102	Rectal	55	Metastatic	FOLFOX	IV	Mut	WT	WT	Mut
CRC-106	Colon	57	Metastatic	FOLFOX plus bevacizumab	IV	WT	WT	WT	WT
CRC-108	Colon	44	Metastatic	Capecitabine, oxaliplatin plus bevacizumab	IV	Mut	WT	WT	WT
CRC-114	Colon	70	Primary	None	III	WT	WT	WT	WT
CRC-125	Rectal	58	Metastatic	Unknown	IV	WT	WT	WT	Mut
CRC-138	Colon	78	Metastatic	None	IV	Mut	WT	WT	Mut
CRC-166	Rectal	41	Metastatic	FOLFOX plus bevacizumab	IV	WT	WT	WT	WT